Stephen A Boorjian

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/6561413/publications.pdf

Version: 2024-02-01

248	8,250	46918	64668
papers	citations	47 h-index	79 g-index

250	250	250	9047
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Prevalence, Predictors, and Oncologic Outcomes of Pelvic Organ Involvement in Women Undergoing Radical Cystectomy. Archives of Pathology and Laboratory Medicine, 2023, 147, 202-207.	1.2	3
2	A contemporary guide to chromosomal copy number profiling in the diagnosis of renal cell carcinoma. Urologic Oncology: Seminars and Original Investigations, 2022, 40, 512-524.	0.8	6
3	Defining radical cystectomy using the ICD-10 procedure coding system. Urologic Oncology: Seminars and Original Investigations, 2022, 40, 165.e17-165.e22.	0.8	6
4	Role of Lymphadenectomy during Radical Cystectomy for Nonmuscle-Invasive Bladder Cancer: Results from a Multi-Institutional Experience. Journal of Urology, 2022, 207, 551-558.	0.2	7
5	A Clinical Decision Aid to Support Personalized Treatment Selection for Patients with Clinical T1 Renal Masses: Results from a Multi-institutional Competing-risks Analysis. European Urology, 2022, 81, 576-585.	0.9	21
6	CT findings and diagnostic performance of upper urinary tract carcinoma in situ. European Radiology, 2022, 32, 3269-3279.	2.3	1
7	The Association of Trainee Involvement in Radical Cystectomy With Perioperative and Oncologic Outcomes. Urology, 2022, , .	0.5	0
8	Outcomes following cytoreductive nephrectomy without immediate postoperative systemic therapy for patients with synchronous metastatic renal cell carcinoma. Urologic Oncology: Seminars and Original Investigations, 2022, 40, 166.e1-166.e8.	0.8	5
9	Renal Neoplasia in Polycystic Kidney Disease: An Assessment of Tuberous Sclerosis Complexâ€“associated Renal Neoplasia and PKD1/TSC2 Contiguous Gene Deletion Syndrome. European Urology, 2022, 81, 229-233.	0.9	12
10	Antiadenovirus Antibodies Predict Response Durability to Nadofaragene Firadenovec Therapy in BCG-unresponsive Nonâ€“muscle-invasive Bladder Cancer: Secondary Analysis of a Phase 3 Clinical Trial. European Urology, 2022, 81, 223-228.	0.9	8
11	Pentafecta for Radical Nephroureterectomy in Patients with High-Risk Upper Tract Urothelial Carcinoma: A Proposal for Standardization of Quality Care Metrics. Cancers, 2022, 14, 1781.	1.7	1
12	Cytogenetics of spermatocytic tumors with a discussion of gain of chromosome 12p in anaplastic variants. Human Pathology, 2022, 124, 85-95.	1.1	2
13	Defining the Impact of Family History on Detection of High-grade Prostate Cancer in a Large Multi-institutional Cohort. European Urology, 2022, 82, 163-169.	0.9	14
14	Does Ureteral Stent Drainage Prior to Cystectomy Increase the Risk of Subsequent Upper Tract Urothelial Carcinoma and Ureteral Complications?. Urology, 2021, 153, 215-220.	0.5	1
15	Prospective validation of microseminoproteinâ€Î²2 added to the 4Kscore in predicting highâ€grade prostate cancer in an international multicentre cohort. BJU International, 2021, 128, 218-224.	1.3	3
16	Renal neoplasia with papillary architecture involving the pelvicalyceal system. Human Pathology, 2021, 107, 46-57.	1.1	7
17	Association of intraoperative hypothermia with oncologic outcomes following radical cystectomy. Urologic Oncology: Seminars and Original Investigations, 2021, 39, 370.e1-370.e8.	0.8	0
18	Creation of a primary tumor tissue expression biomarker-augmented prognostic model for patients with metastatic renal cell carcinoma. Urologic Oncology: Seminars and Original Investigations, 2021, 39, 135.e1-135.e8.	0.8	2

#	Article	IF	Citations
19	Grading Chromophobe Renal Cell Carcinoma: Evidence for a Four-tiered Classification Incorporating Coagulative Tumor Necrosis. European Urology, 2021, 79, 225-231.	0.9	25
20	Intravesical nadofaragene firadenovec gene therapy for BCG-unresponsive non-muscle-invasive bladder cancer: a single-arm, open-label, repeat-dose clinical trial. Lancet Oncology, The, 2021, 22, 107-117.	5.1	172
21	Defining the Most Informative Intermediate Clinical Endpoints for Patients Treated with Salvage Radiotherapy for Prostate-specific Antigen Rise After Radical Prostatectomy. European Urology Oncology, 2021, 4, 301-304.	2.6	2
22	Incidence and predictors of occult preoperative deep vein thrombosis at radical cystectomy for urothelial carcinoma. Canadian Urological Association Journal, 2021, 15, E471-E475.	0.3	1
23	Collaborative Review: Factors Influencing Treatment Decisions for Patients with a Localized Solid Renal Mass. European Urology, 2021, 80, 575-588.	0.9	48
24	Development of a technique for evaluating the presence of malignant cells in prostatic fluid during robotic prostatectomy. Urologic Oncology: Seminars and Original Investigations, 2021, 39, 192.e1-192.e6.	0.8	1
25	The current landscape of salvage therapies for patients with bacillus Calmette-GuÃ©rin unresponsive nonmuscle invasive bladder cancer. Current Opinion in Urology, 2021, 31, 178-187.	0.9	11
26	Urinary-based tumor markers enhance microhematuria risk stratification according to baseline bladder cancer prevalence. Urologic Oncology: Seminars and Original Investigations, 2021, 39, 787.e1-787.e7.	0.8	6
27	Cost-Effectiveness Analysis of Pembrolizumab for Bacillus Calmette-GuÃ©rin-Unresponsive Carcinoma In Situ of the Bladder. Journal of Urology, 2021, 205, 1326-1335.	0.2	14
28	Differential prognostic impact of different Gleason patterns in grade group 4 in radical prostatectomy specimens. European Journal of Surgical Oncology, 2021, 47, 1172-1178.	0.5	7
29	ASO Author Reflections: Is There Any Difference Among Various Gleason Scores Classified as Grade Group 4 Prostate Cancer?. Annals of Surgical Oncology, 2021, 28, 9188-9189.	0.7	0
30	Prognostic Impact of Different Gleason Patterns on Biopsy Within Grade Group 4 Prostate Cancer. Annals of Surgical Oncology, 2021, 28, 9179-9187.	0.7	3
31	When Less Is More: The Comparative Effectiveness of Partial Versus Radical Nephrectomy. European Urology, 2021, 79, 781-782.	0.9	1
32	Renal Neoplasia in Tuberous Sclerosis: A Study of 41 Patients. Mayo Clinic Proceedings, 2021, 96, 1470-1489.	1.4	31
33	Assessment of isochromosome 12p and 12p abnormalities in germ cell tumors using fluorescence in situ hybridization, single-nucleotide polymorphism arrays, and next-generation sequencing/mate-pair sequencing. Human Pathology, 2021, 112, 20-34.	1.1	19
34	100 years of Bacillus Calmetteâ€“GuÃ©rin immunotherapy: from cattle to COVID-19. Nature Reviews Urology, 2021, 18, 611-622.	1.9	80
35	The association of salvage intravesical therapy following BCG with pathologic outcomes and survival after radical cystectomy for patients with high-grade non-muscle invasive bladder cancer: A multi-institution analysis. Urologic Oncology: Seminars and Original Investigations, 2021, 39, 436.e1-436.e8.	0.8	6
36	Assessing the Impact of Hospital Dismissal Summary Readability on Patient Outcomes Following Prostatectomy. Urology, 2021, , .	0.5	1

#	Article	IF	Citations
37	Individual Patient Data Meta-analysis of Discrimination of the Four Kallikrein Panel Associated With the Inclusion of Prostate Volume. Urology, 2021, , .	0.5	1
38	Bim Expression in Peritumoral Lymphocytes is Associated with Survival in Patients with Metastatic Clear Cell Renal Cell Carcinoma. Kidney Cancer, 2021, 5, 129-135.	0.2	0
39	Partial versus radical nephrectomy in clinical T2 renal masses. International Journal of Urology, 2021, 28, 1149-1154.	0.5	14
40	The Impact of Upper Tract Urothelial Carcinoma Diagnostic Modality on Intravesical Recurrence after Radical Nephroureterectomy: A Single Institution Series and Updated Meta-Analysis. Journal of Urology, 2021, 206, 558-567.	0.2	27
41	Reply by Authors. Journal of Urology, 2021, 206, 567-567.	0.2	0
42	A Contemporary Analysis of Urethral Recurrence following Radical Cystectomy. Journal of Urology, 2021, 206, 970-977.	0.2	8
43	Collecting duct carcinoma: A singleâ€institution retrospective study. Urologic Oncology: Seminars and Original Investigations, 2021, 40, 13.e9-13.e18.	0.8	4
44	Assessment of Risk of Hereditary Predisposition in Patients With Melanoma and/or Mesothelioma and Renal Neoplasia. JAMA Network Open, 2021, 4, e2132615.	2.8	4
45	Comparative Effectiveness in Perioperative Outcomes of Robotic versus Open Radical Cystectomy: Results from a Multicenter Contemporary Retrospective Cohort Study. European Urology Focus, 2020, 6, 1233-1239.	1.6	33
46	Do Not Learn a Technique, Learn the Biology Underlying the Disease: Techniques Evolve, Biology Prevails. European Urology, 2020, 77, 1-2.	0.9	3
47	Kallikrein markers performance in pretreatment blood to predict early prostate cancer recurrence and metastasis after radical prostatectomy among very highâ€risk men. Prostate, 2020, 80, 51-56.	1.2	5
48	Percutaneous Image-guided Core Needle Biopsy for Upper Tract Urothelial Carcinoma. Urology, 2020, 135, 95-100.	0.5	18
49	Microscopic Hematuria: Diagnosis Is Only Half the Battle. European Urology, 2020, 77, 599-600.	0.9	0
50	Trends in Extended-Duration Venous Thromboembolism Prophylaxis Following Radical Cystectomy. Urology, 2020, 136, 105-111.	0.5	3
51	The association of anxiety and depression with perioperative and oncologic outcomes among patients with clear cell renal cell carcinoma undergoing nephrectomy. Urologic Oncology: Seminars and Original Investigations, 2020, 38, 41.e19-41.e27.	0.8	8
52	Safety and Efficacy of Retrograde Pyeloperfusion for Ureteral Protection during Renal Tumor Cryoablation. Journal of Vascular and Interventional Radiology, 2020, 31, 1249-1255.	0.2	9
53	Renal Cell Carcinoma with Inferior Vena Cava Extension: Can Classification Be Optimized to Predict Perioperative Outcomes?. Kidney Cancer, 2020, 4, 111-115.	0.2	3
54	Hemosiderin deposition in papillary renal cell carcinoma and its potential to mask enhancement on MRI: analysis of 110 cases. European Radiology, 2020, 30, 6033-6041.	2.3	4

#	Article	IF	Citations
55	Emulating Target Clinical Trials of Radical Nephrectomy With or Without Lymph Node Dissection for Renal Cell Carcinoma. Urology, 2020, 140, 98-106.	0.5	10
56	Long-term outcomes of incidental prostate cancer at radical cystectomy. Urologic Oncology: Seminars and Original Investigations, 2020, 38, 848.e17-848.e22.	0.8	6
57	Treatment Outcomes in Patients With Symptomatic Lymphoceles Following Radical Prostatectomy Depend Upon Size and Presence of Infection. Urology, 2020, 143, 181-185.	0.5	9
58	AUTHOR REPLY. Urology, 2020, 136, 111.	0.5	0
59	Distribution of Molecular Subtypes in Muscle-invasive Bladder Cancer Is Driven by Sex-specific Differences. European Urology Oncology, 2020, 3, 420-423.	2.6	29
60	Simultaneous versus staged partial nephrectomies for bilateral synchronous solid renal masses. Urologic Oncology: Seminars and Original Investigations, 2020, 38, 640.e13-640.e22.	0.8	7
61	Complete Surgical Metastasectomy of Renal Cell Carcinoma in the Post-Cytokine Era. Journal of Urology, 2020, 203, 275-282.	0.2	44
62	Cost-Effectiveness of Maintenance bacillus Calmette-GuÃ©rin for Intermediate and High Risk Nonmuscle Invasive Bladder Cancer. Journal of Urology, 2020, 204, 442-449.	0.2	13
63	The evolving role of lymphadenectomy for bladder cancer: why, when, and how. Translational Andrology and Urology, 2020, 9, 3082-3093.	0.6	7
64	Persistent, long-term risk for ureteroenteric anastomotic stricture formation: the case for long term follow-up. Translational Andrology and Urology, 2020, 9, 142-150.	0.6	18
65	Reply by Authors. Journal of Urology, 2020, 203, 282-282.	0.2	0
66	Screening Postoperative Hemoglobin after Robot-Assisted Radical Prostatectomyâ€”Frequently Used, but Is It Necessary?. Urology Practice, 2020, 7, 554-558.	0.2	0
67	Prognostic evaluation of perinephric fat, renal sinus fat, and renal vein invasion for patients with pathological stage T3a clearâ€cell renal cell carcinoma. BJU International, 2019, 123, 270-276.	1.3	44
68	Open Versus Robotic Cystectomy: A Propensity Score Matched Analysis Comparing Survival Outcomes. Journal of Clinical Medicine, 2019, 8, 1192.	1.0	13
69	Impact of time from biopsy to surgery on complications, functional and oncologic outcomes following radical prostatectomy. International Braz J Urol: Official Journal of the Brazilian Society of Urology, 2019, 45, 468-477.	0.7	15
70	Incidence and risk factors for peritoneal carcinomatosis following open radical cystectomy. Urologic Oncology: Seminars and Original Investigations, 2019, 37, 886-892.	0.8	1
71	Multi-cohort modeling strategies for scalable globally accessible prostate cancer risk tools. BMC Medical Research Methodology, 2019, 19, 191.	1.4	7
72	Discerning Patterns and Quality of Neoadjuvant Chemotherapy Use Among Patients with Muscle-invasive Bladder Cancer. European Urology Oncology, 2019, 2, 497-504.	2.6	23

#	Article	IF	Citations
73	Survival outcomes for patients with surgically induced end-stage renal disease. Canadian Urological Association Journal, 2019, 14, E65-E73.	0.3	0
74	Comprehensive characterization of perioperative reoperation following radical cystectomy. Urologic Oncology: Seminars and Original Investigations, 2019, 37, 292.e11-292.e17.	0.8	7
75	Patient-Reported Outcomes After Percutaneous Renal Ablation: Initial Experience. American Journal of Roentgenology, 2019, 212, 672-676.	1.0	5
76	Reply to Takeshi Takahashi's Letter to the Editor re: Bimal Bhindi, Christine M. Lohse, Phillip J. Schulte, et al. Predicting functional outcomes after partial and radical nephrectomy. Eur Urol 2019;75:766â€“72. Partial Nephrectomy: â€œGeocentrismâ€•of the 21st century in the Church of Urology?. European Urology, 2019, 76, e67-e68.	0.9	0
77	Sarcopenia and Response to Neoadjuvant Chemotherapy for Muscle-Invasive Bladder Cancer. Clinical Genitourinary Cancer, 2019, 17, 216-222.e5.	0.9	21
78	A comparison of adult rhabdomyosarcoma and high-grade neuroendocrine carcinoma of the urinary bladder reveals novel PPP1R12A fusions in rhabdomyosarcoma. Human Pathology, 2019, 88, 48-59.	1.1	2
79	Assessing the Role and Optimal Duration of Hormonal Treatment in Association with Salvage Radiation Therapy After Radical Prostatectomy: Results from a Multi-Institutional Study. European Urology, 2019, 76, 443-449.	0.9	14
80	Clinical predictors and survival outcome of patients receiving suboptimal neoadjuvant chemotherapy and radical cystectomy for muscle-invasive bladder cancer: a single-center experience. World Journal of Urology, 2019, 37, 2409-2418.	1.2	6
81	The natural history of renal cell carcinoma with isolated lymph node metastases following surgical resection from 2006 to 2013. Urologic Oncology: Seminars and Original Investigations, 2019, 37, 932-940.	0.8	5
82	Access to Urological Care and Internet Connectivity in the United States: A Geospatial Analysis. Urology Practice, 2019, 6, 275-281.	0.2	4
83	Systematic Review of Factors Associated with the Utilization of Radical Cystectomy for Bladder Cancer. European Urology Oncology, 2019, 2, 119-125.	2.6	16
84	Delaying Radical Cystectomy After Neoadjuvant Chemotherapy for Muscle-invasive Bladder Cancer is Associated with Adverse Survival Outcomes. European Urology Oncology, 2019, 2, 390-396.	2.6	49
85	Predicting Renal Function Outcomes After Partial and Radical Nephrectomy. European Urology, 2019, 75, 766-772.	0.9	75
86	Propensity-score-matched comparison of soft tissue surgical margins status between open and robotic-assisted radical cystectomy. Urologic Oncology: Seminars and Original Investigations, 2019, 37, 179.e1-179.e7.	0.8	8
87	Implications of micropapillary urothelial carcinoma variant on prognosis following radical cystectomy: A multi-institutional investigation. Urologic Oncology: Seminars and Original Investigations, 2019, 37, 48-56.	0.8	21
88	Evolving Changes in the Delivery of Health Services: A Place for Urological Homecare?. European Urology, 2019, 75, 543-545.	0.9	1
89	Cigarette smoking is associated with adverse pathological response and increased disease recurrence amongst patients with muscleâ€invasive bladder cancer treated with cisplatinâ€based neoadjuvant chemotherapy and radical cystectomy: a singleâ€centre experience. BJU International, 2019, 123, 1011-1019.	1.3	31
90	Frequency and Predictors of Renal Transplantation Among Patients Rendered Surgically Anephric for Sporadic Renal Cancer. Urology, 2019, 126, 134-139.	0.5	1

#	Article	IF	Citations
91	The Microbiome and Genitourinary Cancer: A Collaborative Review. European Urology, 2019, 75, 637-646.	0.9	103
92	A risk-stratified approach to neoadjuvant chemotherapy in muscle-invasive bladder cancer: implications for patients classified with low-risk disease. World Journal of Urology, 2019, 37, 1605-1613.	1.2	9
93	Systematic Review of the Role of Cytoreductive Nephrectomy in the Targeted Therapy Era and Beyond: An Individualized Approach to Metastatic Renal Cell Carcinoma. European Urology, 2019, 75, 111-128.	0.9	138
94	Epidemiology of Renal Cell Carcinoma. European Urology, 2019, 75, 74-84.	0.9	917
95	Association of Partial versus Radical Nephrectomy with Subsequent Hypertension Risk Following Renal Tumor Resection. Journal of Urology, 2019, 202, 69-75.	0.2	8
96	Development and Acceptability Testing of a Patient Decision Aid for Urinary Diversion with Radical Cystectomy. Journal of Urology, 2019, 202, 1001-1007.	0.2	23
97	Cost-Effectiveness of Active Surveillance, Radical Prostatectomy and External Beam Radiotherapy for Localized Prostate Cancer: An Analysis of the ProtecT Trial. Journal of Urology, 2019, 202, 964-972.	0.2	24
98	A Comparison of Bleeding Complications in Patients Undergoing Percutaneous Renal Cryoablation Using Cryoprobes with and without Heat-Based Track Ablation. Journal of Vascular and Interventional Radiology, 2018, 29, 874-879.	0.2	14
99	The Adverse Survival Implications of Bland Thrombus in Renal Cell Carcinoma With Venous Tumor Thrombus. Urology, 2018, 115, 119-124.	0.5	19
100	Synchronous nephronâ€sparing approaches for bilateral renal masses: periâ€operative and renal functional outcomes. BJU International, 2018, 122, 243-248.	1.3	12
101	First-line Systemic Therapy for Metastatic Renal Cell Carcinoma: A Systematic Review and Network Meta-analysis. European Urology, 2018, 74, 309-321.	0.9	51
102	Argininosuccinate Synthetase-1 (ASS1) Loss in High-Grade Neuroendocrine Carcinomas of the Urinary Bladder: Implications for Targeted Therapy with ADI-PEG 20. Endocrine Pathology, 2018, 29, 236-241.	5.2	9
103	Predicting Oncologic Outcomes in Renal Cell Carcinoma After Surgery. European Urology, 2018, 73, 772-780.	0.9	131
104	Radical Nephrectomy with or without Lymph Node Dissection for High Risk Nonmetastatic Renal Cell Carcinoma: A Multi-Institutional Analysis. Journal of Urology, 2018, 199, 1143-1148.	0.2	46
105	Reply to Georgios Papadopoulos, Charalampos Fragkoulis, and Konstantinos Ntoumasâ€™ Letter to the Editor re: Bimal Bhindi, Igor Frank, Ross J. Mason, et al. Oncologic Outcomes for Patients with Residual Cancer at Cystectomy Following Neoadjuvant Chemotherapy: A Pathologic Stage-matched Analysis. Eur Urol 2017;72:660â€“4. European Urology, 2018, 73, e53.	0.9	0
106	The role of lymph node dissection in the management of renal cell carcinoma: a systematic review and metaâ€analysis. BJU International, 2018, 121, 684-698.	1.3	79
107	Comparative Survival following Initial Cytoreductive Nephrectomy versus Initial Targeted Therapy for Metastatic Renal Cell Carcinoma. Journal of Urology, 2018, 200, 528-534.	0.2	59
108	More Extensive Lymph Node Dissection at Radical Prostatectomy is Associated with Improved Outcomes with Salvage Radiotherapy for Rising Prostate-specific Antigen After Surgery: A Long-term, Multi-institutional Analysis. European Urology, 2018, 74, 134-137.	0.9	13

#	Article	IF	Citations
109	Imaging following renal ablation: what can we learn from recurrent tumors?. Abdominal Radiology, 2018, 43, 2750-2755.	1.0	11
110	Increased Utilization of Positron Emission Tomography/Computed Tomography (PET/CT) Imaging and Its Economic Impact for Patients Diagnosed With Bladder Cancer. Clinical Genitourinary Cancer, 2018, 16, e99-e111.	0.9	7
111	Outcomes After Cryoablation Versus Partial Nephrectomy for Sporadic Renal Tumors in a Solitary Kidney: A Propensity Score Analysis. European Urology, 2018, 73, 254-259.	0.9	45
112	Comparison of Abiraterone Acetate and Docetaxel with Androgen Deprivation Therapy in High-risk and Metastatic Hormone-naÃ¯ve Prostate Cancer: A Systematic Review and Network Meta-analysis. European Urology, 2018, 73, 834-844.	0.9	86
113	Utilization and Outcomes of Radical Cystectomy for High-grade Nonâ€“muscle-invasive Bladder Cancer in Elderly Patients. Clinical Genitourinary Cancer, 2018, 16, e79-e97.	0.9	12
114	Guideline of guidelines: asymptomatic microscopic haematuria. BJU International, 2018, 121, 176-183.	1.3	76
115	Use of Concomitant Androgen Deprivation Therapy in Patients Treated with Early Salvage Radiotherapy for Biochemical Recurrence After Radical Prostatectomy: Long-term Results from a Large, Multi-institutional Series. European Urology, 2018, 73, 512-518.	0.9	36
116	The Association Between Sarcopenia and Oncologic Outcomes After Radical Prostatectomy. Clinical Genitourinary Cancer, 2018, 16, e629-e636.	0.9	28
117	Reply to Giulia I. Lane and Badrinath Konety's Letter to the Editor re: Bimal Bhindi, Igor Frank, Ross J. Mason, et al. Oncologic Outcomes for Patients with Residual Cancer at Cystectomy Following Neoadjuvant Chemotherapy: A Pathologic Stage-matched Analysis. Eur Urol 2017;72:660â€“4. European Urology, 2018, 73, e70-e71.	0.9	0
118	Perioperative Morbidity of Lymph Node Dissection for Renal Cell Carcinoma: A Propensity Scoreâ€“based Analysis. European Urology, 2018, 73, 469-475.	0.9	10
119	Adverse Pathology After Neoadjuvant Chemotherapy and Radical Cystectomy: The Role of Adjuvant Chemotherapy. Clinical Genitourinary Cancer, 2018, 16, 64-71.e5.	0.9	7
120	Impact of Early Salvage Radiation Therapy in Patients with Persistently Elevated or Rising Prostate-specific Antigen After Radical Prostatectomy. European Urology, 2018, 73, 436-444.	0.9	60
121	Kidney Cancer Research Network of Canada (KCRNC) consensus statement on the role of cytoreductive nephrectomy for patients with metastatic renal cell carcinoma. Canadian Urological Association Journal, 2018, 13, 166-174.	0.3	10
122	Systematic Review of Comorbidity and Competing-risks Assessments for Bladder Cancer Patients. European Urology Oncology, 2018, 1, 91-100.	2.6	46
123	Staging the Host: Personalizing Risk Assessment for Radical Cystectomy Patients. European Urology Oncology, 2018, 1, 292-304.	2.6	54
124	Heterogeneity of risk within Gleason 4â€‰+â€‰4, 4â€‰+â€‰5 and 5â€‰+â€‰4 prostate cancer. Scandinavian Journal of Urology, 2018, 52, 340-348.	0.6	6
125	Radical Versus Partial Nephrectomy for cT1 Renal Cell Carcinoma. European Urology, 2018, 74, 825-832.	0.9	57
126	Risk prediction models for cancer-specific survival following cytoreductive nephrectomy in the contemporary era. Urologic Oncology: Seminars and Original Investigations, 2018, 36, 499.e1-499.e7.	0.8	6

#	Article	IF	Citations
127	Examining the association between adiposity and biochemical recurrence after radical prostatectomy. Canadian Urological Association Journal, 2018, 12, E331-7.	0.3	3
128	A Contemporary Prostate Biopsy Risk Calculator Based on Multiple Heterogeneous Cohorts. European Urology, 2018, 74, 197-203.	0.9	93
129	The Probability of Aggressive Versus Indolent Histology Based on Renal Tumor Size: Implications for Surveillance and Treatment. European Urology, 2018, 74, 489-497.	0.9	93
130	The dog as an animal model for bladder and urethral urothelial carcinoma: Comparative epidemiology and histology. Oncology Letters, 2018, 16, 1641-1649.	0.8	17
131	The Temporal Association of Robotic Surgical Diffusion with Overtreatment of the Small Renal Mass. Journal of Urology, 2018, 200, 981-988.	0.2	30
132	Vaginal cuff recurrence after radical cystectomy: an under - studied site of bladder cancer relapse. International Braz J Urol: Official Journal of the Brazilian Society of Urology, 2018, 44, 491-499.	0.7	3
133	The Association of Aspirin Use with Survival Following Radical Cystectomy. Journal of Urology, 2018, 200, 1014-1021.	0.2	12
134	Percutaneous Cryoablation of Solitary, Sporadic Renal Cell Carcinoma: Outcome Analysis Based on Clear-Cell versus Papillary Subtypes. Journal of Vascular and Interventional Radiology, 2018, 29, 1122-1126.	0.2	11
135	Temporal trends in venous thromboembolism after radical cystectomy. Urologic Oncology: Seminars and Original Investigations, 2018, 36, 361.e15-361.e21.	0.8	12
136	Symptomatic Venous Thromboembolism is Associated with Inferior Survival among Patients Undergoing Nephrectomy with Inferior Vena Cava Tumor Thrombectomy for Renal Cell Carcinoma. Journal of Urology, 2018, 200, 520-527.	0.2	14
137	Increased utilization of external beam radiotherapy relative to cystectomy for localized, muscle-invasive bladder cancer: a SEER analysis. Bladder, 2018, 5, e34.	0.6	2
138	Application of the Stage, Size, Grade, and Necrosis (SSIGN) Score for Clear Cell Renal Cell Carcinoma in Contemporary Patients. European Urology, 2017, 71, 665-673.	0.9	80
139	Renal Cell Carcinoma with Isolated Lymph Node Involvement: Long-term Natural History and Predictors of Oncologic Outcomes Following Surgical Resection. European Urology, 2017, 72, 300-306.	0.9	69
140	Impact of Radical Prostatectomy on Long-Term Oncologic Outcomes in a Matched Cohort of Men with Pathological Node Positive Prostate Cancer Managed by Castration. Journal of Urology, 2017, 198, 86-91.	0.2	20
141	Defining the Prevalence of Asymptomatic Microscopic Hematuria Among Women With Symptomatic Pelvic Organ Prolapse: Implications for Recommending Subsequent Diagnostic Evaluation. Urology, 2017, 103, 68-72.	0.5	2
142	Are We Using the Best Tumor Size Cut-points for Renal Cell Carcinoma Staging?. Urology, 2017, 109, 121-126.	0.5	25
143	Severity of Preoperative Proteinuria is a Risk Factor for Overall Mortality in Patients Undergoing Nephrectomy. Journal of Urology, 2017, 198, 795-802.	0.2	8
144	Outcomes Following Radical Cystectomy for Plasmacytoid Urothelial Carcinoma: Defining the Need for Improved Local Cancer Control. Urology, 2017, 102, 143-147.	0.5	28

#	Article	IF	Citations
145	Impact of Postoperative Radiotherapy in Men with Persistently Elevated Prostate-specific Antigen After Radical Prostatectomy for Prostate Cancer: A Long-term Survival Analysis. European Urology, 2017, 72, 910-917.	0.9	21
146	Renal functional outcomes in patients undergoing percutaneous cryoablation or partial nephrectomy for a solitary renal mass. BJU International, 2017, 120, 544-549.	1.3	19
147	Oncologic Outcomes for Patients with Residual Cancer at Cystectomy Following Neoadjuvant Chemotherapy: A Pathologic Stage-matched Analysis. European Urology, 2017, 72, 660-664.	0.9	77
148	Association of Distance to Treatment Facility With Survival and Quality Outcomes After Radical Cystectomy: A Multi-Institutional Study. Clinical Genitourinary Cancer, 2017, 15, 689-695.e2.	0.9	14
149	Comprehensive assessment of renal tumour complexity in a large percutaneous cryoablation cohort. BJU International, 2017, 119, 905-912.	1.3	14
150	Percutaneous Cryoablation of Renal Cell Carcinoma with Sinus Vein Involvement Based on Preprocedural Imaging. Journal of Vascular and Interventional Radiology, 2017, 28, 1651-1657.	0.2	3
151	Long-term Follow-up of a Matched Cohort Study Evaluating the Role of Adjuvant Radiotherapy for Organ-confined Prostate Cancer With a Positive Surgical Margin. Urology, 2017, 109, 145-152.	0.5	4
152	Radical cystectomy for recurrent urothelial carcinoma after prior partial cystectomy: perioperative and oncologic outcomes. World Journal of Urology, 2017, 35, 1879-1884.	1.2	1
153	The Association Between Vasectomy and Prostate Cancer. JAMA Internal Medicine, 2017, 177, 1273.	2.6	31
154	Independent Validation of the American Joint Committee on Cancer 8th Edition Prostate Cancer Staging Classification. Journal of Urology, 2017, 198, 1286-1294.	0.2	24
155	Oncologic surveillance following radical cystectomy: an individualized risk-based approach. World Journal of Urology, 2017, 35, 1863-1869.	1.2	8
156	Long-term Impact of Adjuvant Versus Early Salvage Radiation Therapy in pT3N0 Prostate Cancer Patients Treated with Radical Prostatectomy: Results from a Multi-institutional Series. European Urology, 2017, 71, 886-893.	0.9	77
157	Renal fossa recurrence after nephrectomy for renal cell carcinoma: prognostic features and oncological outcomes. BJU International, 2017, 119, 116-127.	1.3	33
158	Primum Non Nocere: Critically Assessing the Morbidity of Prostate Biopsy. European Urology, 2017, 71, 366-367.	0.9	2
159	Lymph Node Dissection is Not Associated with Improved Survival among Patients Undergoing Cytoreductive Nephrectomy for Metastatic Renal Cell Carcinoma: A Propensity Score Based Analysis. Journal of Urology, 2017, 197, 574-579.	0.2	41
160	Radical Nephrectomy With or Without Lymph Node Dissection for Nonmetastatic Renal Cell Carcinoma: A Propensity Score-based Analysis. European Urology, 2017, 71, 560-567.	0.9	58
161	Evaluation of beta-blockers and survival among hypertensive patients with renal cell carcinoma. Urologic Oncology: Seminars and Original Investigations, 2017, 35, 36.e1-36.e6.	0.8	9
162	Urinary collecting system invasion is associated with poor survival in patients with clearâ€cell renal cell carcinoma. BJU International, 2017, 119, 585-590.	1.3	15

#	Article	IF	Citations
163	Systematic Review on the Fate of the Remnant Urothelium after Radical Cystectomy. European Urology, 2017, 71, 545-557.	0.9	72
164	Complications and Outcomes Associated With Surgical Management of Renal Cell Carcinoma Involving the Liver: A Matched Cohort Study. Urology, 2017, 99, 155-161.	0.5	17
165	Intravesical chemotherapy use after radical nephroureterectomy: A national survey of urologic oncologists. Urologic Oncology: Seminars and Original Investigations, 2017, 35, 113.e1-113.e7.	0.8	21
166	Identification of Site-specific Recurrence Following Primary Radiation Therapy for Prostate Cancer Using C-11 Choline Positron Emission Tomography/Computed Tomography: A Nomogram for Predicting Extrapelvic Disease. European Urology, 2017, 71, 340-348.	0.9	51
167	Intravesical formalin for hemorrhagic cystitis: A contemporary cohort. Canadian Urological Association Journal, 2017, 11, 79.	0.3	24
168	Intravesical rAdâ€“IFNÎ±/Syn3 for Patients With High-Grade, Bacillus Calmette-Guerinâ€“Refractory or Relapsed Nonâ€“Muscle-Invasive Bladder Cancer: A Phase II Randomized Study. Journal of Clinical Oncology, 2017, 35, 3410-3416.	0.8	124
169	Safety and efficacy of intravesical alum for intractable hemorrhagic cystitis: a contemporary evaluation. International Braz J Urol: Official Journal of the Brazilian Society of Urology, 2016, 42, 1144-1149.	0.7	29
170	Intravesical silver nitrate for refractory hemorrhagic cystitis. Turkish Journal of Urology, 2016, 42, 197-201.	1.3	19
171	Oncological outcomes following radical prostatectomy for patients with pT4 prostate cancer. International Braz J Urol: Official Journal of the Brazilian Society of Urology, 2016, 42, 1091-1098.	0.7	7
172	Ureteroarterial Fistulas After Robotic and Open Radical Cystectomy. Journal of Endourology Case Reports, 2016, 2, 48-51.	0.3	8
173	Evaluation of <scp>pT</scp>0 prostate cancer in patients undergoing radical prostatectomy. BJU International, 2016, 118, 379-383.	1.3	7
174	Radiographic size of retroperitoneal lymph nodes predicts pathological nodal involvement for patients with renal cell carcinoma: development of a risk prediction model. BJU International, 2016, 118, 742-749.	1.3	32
175	Risk Factors and Microbial Distribution of Urinary Tract Infections Following Radical Cystectomy. Urology, 2016, 94, 96-101.	0.5	36
176	Predicting the 5-Year Risk of Biochemical Relapse After Postprostatectomy Radiation Therapy in â‰¥PT2, pN0 Patients With a Comprehensive Tumor Control Probability Model. International Journal of Radiation Oncology Biology Physics, 2016, 96, 333-340.	0.4	16
177	Concordance of Pathologic Features Between Metastatic Sites and the Primary Tumor in Surgically Resected Metastatic Renal Cell Carcinoma. Urology, 2016, 96, 106-113.	0.5	9
178	Malignant ureteroenteric anastomotic stricture following radical cystectomy with urinary diversion: Patterns, risk factors, and outcomes. Urologic Oncology: Seminars and Original Investigations, 2016, 34, 485.e1-485.e6.	0.8	13
179	Safety and Efficacy of Extended Duration of Thromboembolic Prophylaxis Following Radical Cystectomy: An Initial Institutional Experience. Urology Practice, 2016, 3, 462-467.	0.2	5
180	Surgical Management and Oncologic Outcomes of Recurrent Venous Tumor Thrombus after Prior Nephrectomy for Renal Cell Carcinoma. European Urology Focus, 2016, 2, 625-630.	1.6	6

#	Article	IF	Citations
181	Characterization of perioperative infection risk among patients undergoing radical cystectomy: Results from the national surgical quality improvement program. Urologic Oncology: Seminars and Original Investigations, 2016, 34, 532.e13-532.e19.	0.8	35
182	Paraneoplastic syndromes are associated with adverse prognosis among patients with renal cell carcinoma undergoing nephrectomy. World Journal of Urology, 2016, 34, 1465-1472.	1.2	19
183	The importance of clinical stage among patients with a complete pathologic response at radical cystectomy after neoadjuvant chemotherapy. World Journal of Urology, 2016, 34, 1561-1566.	1.2	5
184	Pre-treatment neutrophil-to-lymphocyte ratio predicts tumor pathology in newly diagnosed renal tumors. World Journal of Urology, 2016, 34, 1693-1699.	1.2	17
185	Risk Stratification of pN+ Prostate Cancer after Radical Prostatectomy from a Large Single Institutional Series with Long-Term Followup. Journal of Urology, 2016, 195, 1773-1778.	0.2	37
186	Oncologic surveillance in bladder cancer following radical cystectomy: A systematic review and meta-analysis. Urologic Oncology: Seminars and Original Investigations, 2016, 34, 236.e13-236.e21.	0.8	6
187	Decreased Skeletal Muscle Mass is Associated with an Increased Risk of Mortality after Radical Nephrectomy for Localized Renal Cell Cancer. Journal of Urology, 2016, 195, 270-276.	0.2	104
188	The association of ABO blood type with disease recurrence and mortality among patients with urothelial carcinoma of the bladder undergoing radical cystectomy. Urologic Oncology: Seminars and Original Investigations, 2016, 34, 4.e1-4.e9.	0.8	19
189	Perioperative management and oncological outcomes following radical cystectomy for bladder cancer: a matched retrospective cohort study. Canadian Journal of Anaesthesia, 2016, 63, 584-595.	0.7	24
190	Standardizing the Definition of Biochemical Recurrence after Radical Prostatectomyâ€"What Prostate Specific Antigen Cut Point Best Predicts a Durable Increase and Subsequent Systemic Progression?. Journal of Urology, 2016, 195, 1754-1759.	0.2	46
191	Efficacy and Safety of Intraoperative Tranexamic Acid Infusion for Reducing Blood Transfusion During Open Radical Cystectomy. Urology, 2016, 92, 57-62.	0.5	30
192	Impact of a family history of prostate cancer on clinicopathologic outcomes and survival following radical prostatectomy. World Journal of Urology, 2016, 34, 1115-1122.	1.2	14
193	Predicting survival of men with recurrent prostate cancer after radical prostatectomy. European Journal of Cancer, 2016, 54, 27-34.	1.3	26
194	Assessing the Optimal Timing for Early Salvage Radiation Therapy in Patients with Prostate-specific Antigen Rise After Radical Prostatectomy. European Urology, 2016, 69, 728-733.	0.9	102
195	Comprehensive Characterization of the Perioperative Morbidity of Cytoreductive Nephrectomy. European Urology, 2016, 69, 84-91.	0.9	47
196	Gender and Bladder Cancer: A Collaborative Review of Etiology, Biology, and Outcomes. European Urology, 2016, 69, 300-310.	0.9	460
197	Safety and efficacy of extended-duration thromboembolic prophylaxis following radical cystectomy.. Journal of Clinical Oncology, 2016, 34, 389-389.	0.8	0
198	Incidence, timing, and risk factors for infection after radical cystectomy: Results from the National Surgical Quality Improvement Program.. Journal of Clinical Oncology, 2016, 34, 445-445.	0.8	0

#	Article	IF	Citations
199	Clinicopathologic characteristics and survival for adult renal sarcoma: A population-based study. Urologic Oncology: Seminars and Original Investigations, 2015, 33, 505.e15-505.e20.	0.8	7
200	Comparative impact of continent and incontinent urinary diversion on longâ€term renal function after radical cystectomy in patients with preoperative chronic kidney disease 2 and chronic kidney disease 3a. International Journal of Urology, 2015, 22, 651-656.	0.5	33
201	Management of T1 Urothelial Carcinoma of the Bladder: What Do We Know and What Do We Need To Know?. Bladder Cancer, 2015, 2, 1-14.	0.2	6
202	Clinical and radiographic predictors of the need for inferior vena cava resection during nephrectomy for patients with renal cell carcinoma and caval tumour thrombus. BJU International, 2015, 116, 388-396.	1.3	66
203	Longâ€term results of radical cystectomy and role of adjuvant chemotherapy for small cell carcinoma of the bladder. International Journal of Urology, 2015, 22, 549-554.	0.5	36
204	The Estrogen Pathway: Estrogen Receptor-Î±, Progesterone Receptor, and Estrogen Receptor-Î² Expression in Radical Cystectomy Urothelial Cell Carcinoma Specimens. Clinical Genitourinary Cancer, 2015, 13, 476-484.	0.9	19
205	Survivorship and Improving Quality of Life in Men with Prostate Cancer. European Urology, 2015, 68, 374-383.	0.9	91
206	Temporal Trends and Factors Associated with Systemic Therapy after Cytoreductive Nephrectomy: An Analysis of the National Cancer Database. Journal of Urology, 2015, 193, 1108-1113.	0.2	32
207	The Impact of Targeted Therapy on Management of Metastatic Renal Cell Carcinoma: Trends in Systemic Therapy and Cytoreductive Nephrectomy Utilization. Urology, 2015, 85, 442-451.	0.5	35
208	Re: Overall Survival Advantage with Partial Nephrectomy: A Bias of Observational Data?. European Urology, 2015, 67, 593.	0.9	0
209	Mortality after Radical Cystectomy: Impact of Obesity Versus Adiposity after Adjusting for Skeletal Muscle Wasting. Journal of Urology, 2015, 193, 1507-1513.	0.2	60
210	The Cistrome and Gene Signature of Androgen Receptor Splice Variants in Castration Resistant Prostate Cancer Cells. Journal of Urology, 2015, 193, 690-698.	0.2	57
211	The association of statin therapy with clinicopathologic outcomes and survival among patients with localized renal cell carcinoma undergoing nephrectomy. Urologic Oncology: Seminars and Original Investigations, 2015, 33, 388.e11-388.e18.	0.8	16
212	Evaluation of current surveillance guidelines following radical cystectomy and proposal of a novel risk-based approach. Urologic Oncology: Seminars and Original Investigations, 2015, 33, 339.e1-339.e8.	0.8	21
213	Impact of Rhabdoid Differentiation on Prognosis for Patients with Grade 4 Renal Cell Carcinoma. European Urology, 2015, 68, 5-7.	0.9	25
214	Efficiency, Satisfaction, and Costs for Remote Video Visits Following Radical Prostatectomy: A Randomized Controlled Trial. European Urology, 2015, 68, 729-735.	0.9	203
215	CT Urography for Diagnosis of Upper Urinary Tract Urothelial Carcinoma: Are Both Nephrographic and Excretory Phases Necessary?. American Journal of Roentgenology, 2015, 205, W320-W327.	1.0	29
216	Percutaneous Clinical T1a Renal Mass Ablation in the Octogenarian and Nonagenarian: Oncologic Outcomes and Morbidity. Journal of Endourology, 2015, 29, 671-676.	1.1	18

#	Article	IF	Citations
217	Radical prostatectomy in high-risk and locally advanced prostate cancer: Mayo Clinic perspective. Urologic Oncology: Seminars and Original Investigations, 2015, 33, 235-244.	0.8	27
218	The association between metformin use and oncologic outcomes among surgically treated diabetic patients with localized renal cell carcinoma. Urologic Oncology: Seminars and Original Investigations, 2015, 33, 67.e15-67.e23.	0.8	23
219	Evaluation of post-operative complications and prolonged length of stay following cytoreductive nephrectomy.. Journal of Clinical Oncology, 2015, 33, 420-420.	0.8	0
220	The impact of rhabdoid differentiation on prognosis in patients with grade 4 renal cell carcinoma.. Journal of Clinical Oncology, 2015, 33, 494-494.	0.8	0
221	Predicting survival after radical cystectomy: Validation of the SPARC score.. Journal of Clinical Oncology, 2015, 33, 326-326.	0.8	2
222	Preoperative neutrophil-lymphocyte ratio predicts death among patients with localized clear cell renal carcinoma undergoing nephrectomy. Urologic Oncology: Seminars and Original Investigations, 2014, 32, 1277-1284.	0.8	46
223	Non-O Blood Type Is Associated With an Increased Risk of Venous Thromboembolism After Radical Cystectomy. Urology, 2014, 83, 140-145.	0.5	16
224	Predicting Survival of Patients with Node-positive Prostate Cancer Following Multimodal Treatment. European Urology, 2014, 65, 554-562.	0.9	86
225	High rates of advanced disease, complications, and decline of renal function after radical nephroureterectomy. Urologic Oncology: Seminars and Original Investigations, 2014, 32, 47.e9-47.e14.	0.8	55
226	The presence of extracapsular extension is associated with an increased risk of death from prostate cancer after radical prostatectomy for patients with seminal vesicle invasion and negative lymph nodes. Urologic Oncology: Seminars and Original Investigations, 2014, 32, 26.e1-26.e7.	0.8	61
227	Long-Term Renal Function Outcomes after Radical Cystectomy. Journal of Urology, 2014, 191, 619-625.	0.2	97
228	Cystectomy for Refractory Hemorrhagic Cystitis: Contemporary Etiology, Presentation and Outcomes. Journal of Urology, 2014, 192, 1687-1692.	0.2	73
229	Diabetes Mellitus is Independently Associated with an Increased Risk of Mortality in Patients with Clear Cell Renal Cell Carcinoma. Journal of Urology, 2014, 192, 1620-1627.	0.2	33
230	Outcome of patients with micropapillary urothelial carcinoma following radical cystectomy: ERBB2 (HER2) amplification identifies patients with poor outcome. Modern Pathology, 2014, 27, 758-764.	2.9	69
231	Primary Gleason Grade 4 at the Positive Margin Is Associated with Metastasis and Death Among Patients with Gleason 7 Prostate Cancer Undergoing Radical Prostatectomy. European Urology, 2014, 66, 1116-1124.	0.9	34
232	Late Recurrence after Radical Cystectomy: Patterns, Risk Factors and Outcomes. Journal of Urology, 2014, 191, 1256-1261.	0.2	18
233	Pretreatment Neutrophil-to-Lymphocyte Ratio Is Associated with Advanced Pathologic Tumor Stage and Increased Cancer-specific Mortality Among Patients with Urothelial Carcinoma of the Bladder Undergoing Radical Cystectomy. European Urology, 2014, 66, 1157-1164.	0.9	163
234	Prediction of Outcome Following Early Salvage Radiotherapy Among Patients with Biochemical Recurrence After Radical Prostatectomy. European Urology, 2014, 66, 479-486.	0.9	121

#	Article	IF	Citations
235	The Role of Radical Prostatectomy and Lymph Node Dissection in Lymph Nodeâ€“Positive Prostate Cancer: A Systematic Review of the Literature. European Urology, 2014, 66, 191-199.	0.9	100
236	The impact of histology on survival for patients with metastatic renal cell carcinoma undergoing cytoreductive nephrectomy. Indian Journal of Urology, 2014, 30, 38.	0.2	5
237	AUA and NCCN surveillance guidelines for RCC: Do they effectively capture recurrences following nephrectomy?. Journal of Clinical Oncology, 2014, 32, 402-402.	0.8	8
238	EAU and NCCN surveillance guidelines for bladder cancer: Do they effectively capture recurrences following cystectomy?. Journal of Clinical Oncology, 2014, 32, 310-310.	0.8	0
239	Perioperative outcomes following surgical resection of renal cell carcinoma with upper level IVC thrombus: A contemporary multicenter experience.. Journal of Clinical Oncology, 2014, 32, 498-498.	0.8	0
240	Temporal trends and factors associated with receipt of systemic therapy among patients undergoing cytoreductive nephrectomy.. Journal of Clinical Oncology, 2014, 32, 503-503.	0.8	1
241	Diabetes mellitus and risk of cancer-specific mortality among patients with clear cell renal cell carcinoma undergoing nephrectomy.. Journal of Clinical Oncology, 2014, 32, 516-516.	0.8	1
242	Comparative Performance of Comorbidity Indices for Estimating Perioperative and 5-Year All Cause Mortality Following Radical Cystectomy for Bladder Cancer. Journal of Urology, 2013, 190, 55-60.	0.2	104
243	Natural History of Biochemical Recurrence After Radical Prostatectomy with Adjuvant Radiation Therapy. Journal of Urology, 2012, 188, 1761-1766.	0.2	18
244	Detection of Asymptomatic Recurrence During Routine Oncological Followup After Radical Cystectomy is Associated With Improved Patient Survival. Journal of Urology, 2011, 186, 1796-1802.	0.2	46
245	Long-Term Risk of Clinical Progression After Biochemical Recurrence Following Radical Prostatectomy: The Impact of Time from Surgery to Recurrence. European Urology, 2011, 59, 893-899.	0.9	266
246	Expression and significance of androgen receptor coactivators in urothelial carcinoma of the bladder. Endocrine-Related Cancer, 2009, 16, 123-137.	1.6	73
247	Renal cell carcinoma: vena caval involvement. BJU International, 2007, 99, 1239-1244.	1.3	94
248	Unplanned Conversion from Partial to Radical Nephrectomy â€“ An Analysis of Incidence, Etiology, and Risk Factors. Journal of Urology, 0, , .	0.2	1